뉴스벤징가
FDA Signals uniQure Huntington Gene Therapy Data Could Back Accelerated Approval
· 발표
기사 요약
uniQure stock surged after the FDA said three-year AMT-130 data could support accelerated approval for Huntington's disease treatment.
기사 원문에서 발췌했어요.uniQure stock surged after the FDA said three-year AMT-130 data could support accelerated approval for Huntington's disease treatment.
기사 원문에서 발췌했어요.
댓글 —
댓글을 불러오고 있어요…